& invivoscribe

LymphoTrack[®] Low Positive Control and LymphoQuant[®] Internal Control for MiSeq[®] and Ion S5/PGM[™] LymphoTrack Assays

Jeff Panganiban, Presha Shah, Brandon Givens, Edgar Vigil, Maggie Kaminsky, Ying Huang, Kasey Hutt, and Jeffrey E. Miller

Invivoscribe, Inc., San Diego, CA

Introduction

LymphoTrack[®] Assays with the associated LymphoTrack software have been developed for MiSeq[®] and Ion S5[™] platforms. They are able to detect immunoglobulin (Ig) and T-cell receptor (TCR) clonal rearrangements in suspected lymphoproliferative disease (LPD) clinical specimens. The detected sample specific clonal V-(D)-J sequence in baseline specimens can be tracked in the follow-up samples to identify and monitor disease status. Typically, the subject-specific clonal rearrangements in follow-up specimens are present at very low levels (10⁻⁴ or below). When testing these specimens, it is important to include a low positive control (LPC) in the run and to report the estimated clonal cells in a sample. We report the design and development of these controls for LymphoTrack Assays: the LPCs run quality controls, and the LymphoQuant™ internal controls (LQIC) used for estimating clonal cells within a specimen.

Results: Calculated vs. Expected Cell Equiv. for Contrived Samples (10⁻² to 10⁻⁵)



500 1,000 1,500 2,000 2,500 3,000 3,500 **Expected Cell**



Contrived Sample	Expected # of Clonal Cells
10-2	3077
10-3	308
10-4	31
10 ⁻⁵	3

1,000 1,500 2,000 2,500 3,000 3,500 500 **Expected Cell**







Materials and Methods

Two types of LPC and LQIC were developed, one for Ig (IGHV Leader, IGH FR1, IGH FR2, IGH FR3, and IGK), and one for TCR (TRG and TRB). Each LPC consists of clonal positive cell line DNA diluted in clonal negative DNA at ~10⁻⁴ level. Each LQIC is diluted clonal positive cell line DNA at a concentration of about 50 cell equivalent per µL. All LPCs and LQICs can be detected by the LymphoTrack Assays on either the Illumina MiSeq[®] or Thermo Fisher Ion S5/PGM[™] platforms. Multiple lots of LPCs and LQICs were made and lot-to-lot variations were evaluated using contrived samples that were prepared by 10-fold serial dilution of clonal positive cell line DNA into clonal negative DNA at levels ranging from 10⁻² to 10⁻⁵.

Principal of LymphoQuant Internal Control (LQIC)





Results: Intra and Inter Lot Variability for LQIC

Intra-Lot Mean and CV% of Frequency for LQIC Tested by Each LymphoTrack Assay											
Lot N	IGHV Leader		IGH FR1		IGH FR2		IGH FR3		IGK		
	N	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%
1	12	6.16E-03	35.07	2.15E-03	28.12	7.18E-03	18.84	3.78E-03	55.54	4.40E-03	22.15
2	12	6.82E-03	8.56	2.10E-03	28.69	5.68E-03	14.54	3.56E-03	63.63	5.34E-03	23.79

Inter-Lot Mean and CV% of Frequency for LQIC Tested by Each LymphoTrack Assay											
	IGHV L	IGHV Leader		<i>IGH</i> FR1		IGH FR2		FR3	IGK		
N	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	
24	6.49E-03	24.4	2.12E-03	27.8	6.43E-03	20.8	3.67E-03	58.3	4.85E-03	24.7	

Results: Intra and Inter Lot Variability for LPC

Results: Comparison LQIC Results between MiSeq[®] and Ion S5TM

LQIC Frequency Values Tested by LymphoTrack Assays on MiSeq [®] and S5 Platforms									
Assay	MiS	eq®	S5						
	Mean (n=12)	CV%	Mean (n=3)	CV%					
<i>IGH</i> FR1	2.15E-03	28.12	6.47E-03	14.4					
IGH FR2	7.18E-03	18.84	1.06E-02	11.4					
IGH FR3	3.78E-03	55.54	4.64E-03	45.8					

Results: Calculated Clonal Cell Equivalence in Follow-Up Sample

Calculated Clonal Cell Equiv. in Follow-up Sample in the Presence of LQIC Tested by IGH FR3 Assay



Intra-Lot Mean and CV% of Frequency for LPC Tested by Each LymphoTrack Assay											
Lot N	IGHV Leader		<i>IGH</i> FR1		IGH FR2		IGH FR3		IGK		
	N	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%
1	12	1.99E-04	41.4	5.93E-05	66.8	2.61E-04	63.6	1.74E-04	65.5	8.53E-04	14.3
2	12	2.12E-04	44.1	5.73E-05	62.4	2.73E-04	35.7	1.33E-04	40.2	7.55E-04	20.3

Inter-Lot Mean and CV% of Frequency for LPC Tested by Each LymphoTrack Assay

N	IGHV L	.eader	IGH	FR1	IGH F	R2	IGH	FR3	IGK		
	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	Mean	CV%	
24	2.06E-04	42.0	5.83E-05	63.5	2.67E-04	49.8	1.54E-04	58.1	8.06E-04	17.7	

Timepoint

Conclusions

- We have developed two types of controls (LPC and LQIC) for LymphoTrack assays run on the MiSeq[®] and S5 sequencing platforms.
- Both inter- and intra-lot variability were assessed.
- The LQIC allows investigators to estimate clonal cells present in the specimen suggesting potential applications in detect and monitor minimal residual disease.



AMP Global May 16-18 2019 Hong Kong

MiSeg[®] is a registered trademark of Illumina. Inc. Ion S5[™] and Ion PGM[™] are trademarks of ThermoFisher Scientific, Inc.